{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"VNRX","limit":50},"count":50,"signals":[{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":71,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. We believe we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties could","filed_date":"2026-03-31","accession":"0001477932-26-001832","full_text":"https://origin.rootz.global/static/filing/0001477932-26-001832.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":67,"context":"ionRx under the 2015 Stock Incentive Plan, as amended, or the 2015 Plan, vesting, subject to the achievement of certain corporate goals and Mr. Reynolds continued service, in three equal, annual installments from the date of grant. On January 24, 2024 and August 15, 2024, certain of the performance goals were deemed to have been timely met resulting in vesting of rights with respect to 79,650 restric","filed_date":"2025-04-29","accession":"0001477932-25-003069","full_text":"https://origin.rootz.global/static/filing/0001477932-25-003069.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":42,"context":"fy the selection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2025; | | | 3. | Non-Binding Advisory Vote to Approve Named Executive Officer Compensation. To approve, by a non-binding advisory vote, the compensation of the Companys named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy","filed_date":"2025-04-29","accession":"0001477932-25-003069","full_text":"https://origin.rootz.global/static/filing/0001477932-25-003069.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":37,"context":"d in the Registration Statement and the Prospectus, except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or would reasonably be expected to have a material adverse effect on or affecting the assets, business, operations, earnings, properties, condition (financial or otherwise), prospects, stockholders e","filed_date":"2025-04-22","accession":"0001477932-25-002897","full_text":"https://origin.rootz.global/static/filing/0001477932-25-002897.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":70,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. We believe we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties could","filed_date":"2025-03-31","accession":"0001477932-25-002231","full_text":"https://origin.rootz.global/static/filing/0001477932-25-002231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":41,"context":"under the 2015 Stock Incentive Plan, as amended, or the 2015 Plan, vesting, subject to the achievement of certain corporate goals and Mr. Reynolds continued service, over 3-years in three equal installments at 12 months, at 24 months, and at 36 months from the date of grant. On October 4, 2022, Mr. Reynolds was also granted a restricted stock unit award for 200,000 shares of common stock of Volition","filed_date":"2024-05-13","accession":"0001477932-24-002777","full_text":"https://origin.rootz.global/static/filing/0001477932-24-002777.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":46,"context":"fy the selection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2024; | | | 3. | Non-Binding Advisory Vote to Approve Named Executive Officer Compensation. To approve, by a non-binding advisory vote, the compensation of the Companys named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy","filed_date":"2024-05-13","accession":"0001477932-24-002777","full_text":"https://origin.rootz.global/static/filing/0001477932-24-002777.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":54,"context":"** We face competition primarily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences Corporation, Guardant Health, GRAIL Inc., Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Abbott Laboratories Inc., Cepheid Inc., Hologic Corporation, Agilent Technologies In","filed_date":"2024-03-25","accession":"0001477932-24-001453","full_text":"https://origin.rootz.global/static/filing/0001477932-24-001453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":71,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. We believe we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties could","filed_date":"2024-03-25","accession":"0001477932-24-001453","full_text":"https://origin.rootz.global/static/filing/0001477932-24-001453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":9,"context":"y any such recommendation. | | | | 91 | | | | | | Table of Contents | | **ITEM 11.EXECUTIVE COMPENSATION** **Summary Compensation Table** The following table sets forth the principal positions of the named executive officers of the Company and the compensation awarded to, earned by or paid to such persons for all services rendered in all capacities to the Company and its subsidiaries, for the fiscal years ended December","filed_date":"2024-03-25","accession":"0001477932-24-001453","full_text":"https://origin.rootz.global/static/filing/0001477932-24-001453.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":32,"context":"for 49,645 shares of common stock of VolitionRx under the 2015 Plan, vesting, subject to the achievement of certain corporate goals and Mr. Reynolds continued service, over 2-years in two equal installments at 12 months and at 24 months from the date of grant. On October 4, 2022, Mr. Reynolds was granted a restricted stock unit award for 89,000 shares of common stock of VolitionRx under the 2015 Pla","filed_date":"2023-04-28","accession":"0001477932-23-002970","full_text":"https://origin.rootz.global/static/filing/0001477932-23-002970.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":46,"context":"the selection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2023; | | | | 3. | Non-Binding Advisory Vote to Approve Named Executive Officer Compensation. To approve, by a non-binding advisory vote, the compensation of the Companys named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy","filed_date":"2023-04-28","accession":"0001477932-23-002970","full_text":"https://origin.rootz.global/static/filing/0001477932-23-002970.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":13,"context":"ate facing competition primarily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences Corporation, Guardant Health, GRAIL Inc., Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Oncimmune Holdings Plc, Abbott Laboratories Inc., Cepheid Inc., Hologic Corporation,","filed_date":"2023-03-15","accession":"0001477932-23-001497","full_text":"https://origin.rootz.global/static/filing/0001477932-23-001497.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":31,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. | | | | 9 | | | | | | Table of Contents | | We believe we have structured our business operations to comply with applicable legal requirements. However, it is possible that govern","filed_date":"2023-03-15","accession":"0001477932-23-001497","full_text":"https://origin.rootz.global/static/filing/0001477932-23-001497.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":27,"context":"for 49,645 shares of common stock of VolitionRx under the 2015 Plan, vesting, subject to the achievement of certain corporate goals and Mr. Reynolds continued service, over 2-years in two equal installments at 12 months and at 24 months from the date of grant. The amounts disclosed under All Other Compensation consist of (i) $365,277 in deemed compensation, during the year ended December 31, 2021, r","filed_date":"2022-04-28","accession":"0001477932-22-002686","full_text":"https://origin.rootz.global/static/filing/0001477932-22-002686.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":48,"context":"tion of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2022; | | | | | | | | | 3. | Non-Binding Advisory Vote to Approve Named Executive Officer Compensation. To approve, by a non-binding advisory vote, the compensation of the Companys named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy","filed_date":"2022-04-28","accession":"0001477932-22-002686","full_text":"https://origin.rootz.global/static/filing/0001477932-22-002686.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":31,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. We believe we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties could","filed_date":"2022-03-30","accession":"0001477932-22-001740","full_text":"https://origin.rootz.global/static/filing/0001477932-22-001740.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":56,"context":"o ratify the selection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2021;  3.**Non-Binding Advisory Vote to Approve Named Executive Officer Compensation.** To approve, by a non-binding advisory vote, the compensation of the Companys named executive officers, as disclosed in the *Compensation of Named Executive Officers* section of this P","filed_date":"2021-04-29","accession":"0001078782-21-000404","full_text":"https://origin.rootz.global/static/filing/0001078782-21-000404.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":20,"context":"stockholders may lose all or part of their investment. Furthermore, additional risks and uncertainties of which we are currently unaware, or which we currently consider to be immaterial, could have a material adverse effect on our business.* *Certain statements made in this section constitute forward-looking statements, which are subject to numerous risks and uncertainties including those described in this section. Refe","filed_date":"2021-03-22","accession":"0001078782-21-000262","full_text":"https://origin.rootz.global/static/filing/0001078782-21-000262.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":43,"context":"ng Firm.** To ratify the selection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2020;  3.**Advisory Vote to Approve Named Executive Officer Compensation.** To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the Proxy Statement;  4.**Approval of Amendment to 2015 Stock Incentive P","filed_date":"2020-04-29","accession":"0001078782-20-000296","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":17,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. We believe that we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties","filed_date":"2020-02-20","accession":"0001078782-20-000134","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000134.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":37,"context":"ng Firm.** To ratify the selection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2019;  3.**Advisory Vote to Approve Named Executive Officer Compensation.** To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the Proxy Statement;  4.**Approval of Amendment to 2015 Stock Incentive P","filed_date":"2019-04-29","accession":"0001078782-19-000375","full_text":"https://origin.rootz.global/static/filing/0001078782-19-000375.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":17,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations. We believe that we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties","filed_date":"2019-03-13","accession":"0001078782-19-000220","full_text":"https://origin.rootz.global/static/filing/0001078782-19-000220.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":36,"context":"selection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2018;  3.**Advisory Vote on the Compensation of the Companys Named Executive Officers.** To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy Statement;  4.**Ap","filed_date":"2018-07-20","accession":"0001078782-18-000720","full_text":"https://origin.rootz.global/static/filing/0001078782-18-000720.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":17,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations.  We believe that we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties","filed_date":"2018-03-01","accession":"0001078782-18-000250","full_text":"https://origin.rootz.global/static/filing/0001078782-18-000250.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":43,"context":"ection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2017;  *3.* **Advisory Vote on the Compensation of the Companys Named Executive Officers.** To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy Statement; *4.* **","filed_date":"2017-07-24","accession":"0001078782-17-000996","full_text":"https://origin.rootz.global/static/filing/0001078782-17-000996.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":16,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations.  We believe that we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties","filed_date":"2017-03-10","accession":"0001078782-17-000302","full_text":"https://origin.rootz.global/static/filing/0001078782-17-000302.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":41,"context":"ection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ending December 31, 2016;  *3.* **Advisory Vote on the Compensation of the Companys Named Executive Officers.** To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy Statement; *4.* **","filed_date":"2016-08-22","accession":"0001078782-16-003325","full_text":"https://origin.rootz.global/static/filing/0001078782-16-003325.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":17,"context":"to matters such as safe working conditions, industrial safety, and labor laws. We may incur significant costs to comply with such laws and regulations in the future, and lack of compliance could have material adverse effects on our operations.  We believe that we have structured our business operations to comply with applicable legal requirements. However, it is possible that governmental entities or other third parties","filed_date":"2016-03-11","accession":"0001078782-16-002414","full_text":"https://origin.rootz.global/static/filing/0001078782-16-002414.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":15,"context":"commitment for samples costing $50,000, to be provided over a two year period, expiring on April 15, 2017.  f) Legal Proceedings There are no legal proceedings which the Company believes will have a material adverse effect on its financial position. **Note 12 Subsequent Events** On October 6, 2015, 100,000 warrants were exercised at a price of $2.20 per share, giving cash proceeds to the Company of $220,000. As a resul","filed_date":"2015-11-04","accession":"0001078782-15-001736","full_text":"https://origin.rootz.global/static/filing/0001078782-15-001736.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":52,"context":"lection of Sadler, Gibb & Associates, LLC as the Companys independent registered public accounting firm for the year ended December 31, 2015;  *3.* **Advisory Vote on the Compensation of the Companys Named Executive Officers.** To approve, by a non-binding advisory vote, the compensation of our named executive officers, as disclosed in the Compensation of Named Executive Officers section of this Proxy Statement; *4.* **","filed_date":"2015-09-16","accession":"0001078782-15-001479","full_text":"https://origin.rootz.global/static/filing/0001078782-15-001479.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":100,"match_count":15,"context":"commitment for samples costing $50,000, to be provided over a two year period, expiring on April 15, 2017.  f) Legal Proceedings There are no legal proceedings which the Company believes will have a material adverse effect on its financial position. 15 ** VOLITIONRX LIMITED** Notes to the Condensed Consolidated Financial Statements June 30, 2015 and December 31, 2014 (Unaudited) **Note 12 Subsequent Events** On July 22","filed_date":"2015-08-11","accession":"0001078782-15-001246","full_text":"https://origin.rootz.global/static/filing/0001078782-15-001246.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":14,"context":"a small number of blood samples from lung and prostate cancer patients. ______________________ 21 Fraga MF et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nature Genetics, Vol 37 (4), p391-400, 2005 9 NuQ Research Kits  We have launched our first RUO products for use in cell culture in 2014, although we have decided to focus our lim","filed_date":"2015-03-18","accession":"0001078782-15-000395","full_text":"https://origin.rootz.global/static/filing/0001078782-15-000395.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"ity Incentive Plan* As of June 9, 2014, the following Awards have been issued under the Plan: Options over 720,000 shares were granted on November 25, 2011. The options vest in equal six monthly installments over three years commencing 6 months from the date of grant, and expire three years after the vesting dates. The exercise prices are $3 for options vesting in the first year, $4 for options vesti","filed_date":"2014-06-20","accession":"0001078782-14-001124","full_text":"https://origin.rootz.global/static/filing/0001078782-14-001124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":100,"match_count":18,"context":"Proposal 1**: Directors are elected by a plurality of the shares of Common Stock that are present in person or represented by proxy, meaning the nominees receiving the highest number of votes will be elected to the Board of Directors.  **Proposal 2**: The ratification of Sadler, Gibb & Associates, LLC as the Companys independent auditor for the year ended December 31, 2014 requires the approval of a majority of the votes cast. *","filed_date":"2014-06-20","accession":"0001078782-14-001124","full_text":"https://origin.rootz.global/static/filing/0001078782-14-001124.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":96,"match_count":12,"context":"salary that he would have received between the date of termination and the completion of a six month notice period less income tax and National Insurance contributions, payable in equal monthly installments during such notice period. With respect to any severance payment, Mr. Reynolds has an obligation to seek alternative income during the remainder of the notice period and any such income received","filed_date":"2020-04-29","accession":"0001078782-20-000296","full_text":"https://origin.rootz.global/static/filing/0001078782-20-000296.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"risk_factor","strength":86,"match_count":7,"context":"commitment for samples costing $50,000, to be provided over a two year period, expiring on April 15, 2017.  f) Legal Proceedings There are no legal proceedings which the Company believes will have a material adverse effect on its financial position. 15 ** VOLITIONRX LIMITED** Notes to the Condensed Consolidated Financial Statements March 31, 2016 and December 31, 2015 ($ expressed in US dollars) (Unaudited) **Note 10 S","filed_date":"2016-05-13","accession":"0001078782-16-002787","full_text":"https://origin.rootz.global/static/filing/0001078782-16-002787.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"ily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences Corporation, Guardant Health, GRAIL Inc., Natera, Caris Life Sciences, Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Abbott Laboratories Inc., Cepheid Inc., Hologic Corporation, Agilent Technologies In","filed_date":"2026-03-31","accession":"0001477932-26-001832","full_text":"https://origin.rootz.global/static/filing/0001477932-26-001832.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"n which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays. Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition,","filed_date":"2022-11-14","accession":"0001477932-22-008533","full_text":"https://origin.rootz.global/static/filing/0001477932-22-008533.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":80,"match_count":10,"context":"n which the Company operates. As a result of the impacts of the COVID-19 pandemic, the Company has experienced and may continue to experience disruptions to its clinical trials, including patient enrollment and sample collection delays. Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic, the extent to which the pandemic will impact its business, financial condition,","filed_date":"2022-08-10","accession":"0001477932-22-005796","full_text":"https://origin.rootz.global/static/filing/0001477932-22-005796.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"** We face competition primarily from other human-focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences Corporation, Guardant Health, GRAIL Inc., Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Abbott Laboratories Inc., Cepheid Inc., Hologic Corporation, Agilent Technologies In","filed_date":"2025-03-31","accession":"0001477932-25-002231","full_text":"https://origin.rootz.global/static/filing/0001477932-25-002231.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":72,"match_count":9,"context":"rs that nucleosomes in cancer cells have differences in structure from those in healthy cells1. 1 Fraga MF et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nature Genetics, Vol 37 (4), p391-400, 2005 7 Figure 2 Release of nucleosomes into blood Blood nucleosome levels can be raised in conditions other than cancer including in auto-im","filed_date":"2014-03-28","accession":"0001078782-14-000481","full_text":"https://origin.rootz.global/static/filing/0001078782-14-000481.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for 1.05 million. Per the terms of the agreement, 314,406 of the grant is to be repaid, by installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such re","filed_date":"2023-11-14","accession":"0001477932-23-008451","full_text":"https://origin.rootz.global/static/filing/0001477932-23-008451.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for 1.05 million. Per the terms of the agreement, 314,406 of the grant is to be repaid, by installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such re","filed_date":"2022-05-11","accession":"0001477932-22-003197","full_text":"https://origin.rootz.global/static/filing/0001477932-22-003197.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"ate facing competition primarily from other human focused healthcare, pharmaceutical and diagnostic companies such as Exact Sciences Corporation, Guardant Health, GRAIL Inc., Freenome Holdings Inc, CellMax Life, Archer DX Inc., Foundation Medicine Inc., Oncocyte Corporation, OpKo Health Inc., MDNA Life Sciences Inc., Oncimmune Holdings Plc, Abbott Laboratories Inc., Cepheid Inc., Koninklijke Philips","filed_date":"2022-03-30","accession":"0001477932-22-001740","full_text":"https://origin.rootz.global/static/filing/0001477932-22-001740.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"the timely achievement of certain pre-determined corporate goals by the Company and/or its subsidiaries as set forth in the grant documents. The RSUs eligible for vesting shall vest in two equal installments at 12 months and 24 months from the grant date, subject to continued service. These RSUs vest over two years with up to 230,102 units vesting on August 3, 2022, and up to 230,089 units vesting on","filed_date":"2021-11-10","accession":"0001477932-21-008003","full_text":"https://origin.rootz.global/static/filing/0001477932-21-008003.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"strategic_event","strength":64,"match_count":8,"context":"is also a director of Belgian Volition since October 27, 2010, serving as Managing Director between January 18, 2012 and July 24, 2015, a director and CEO of Hypergenomics since March 7, 2011 and was appointed director and CEO of Volition Diagnostics UK Limited, on November 13, 2015. From 2004 until 2011, Mr. Reynolds founded and served as Managing Director and Director of Mining House Limited, where he was responsible for","filed_date":"2016-03-11","accession":"0001078782-16-002414","full_text":"https://origin.rootz.global/static/filing/0001078782-16-002414.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":64,"match_count":8,"context":"cancer cells are different in structure from those in healthy cells.11 _______________________ 11 Fraga MF et al., Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer, Nature Genetics, Vol 37 (4), p391-400, 2005 7 Figure 2 Release of nucleosomes into blood Additionally, blood nucleosome levels are raised in conditions other than cancer including","filed_date":"2013-04-01","accession":"0001078782-13-000597","full_text":"https://origin.rootz.global/static/filing/0001078782-13-000597.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"into an agreement with the Walloon Region government in Belgium for a colorectal cancer research grant for 1.05 million. Per the terms of the agreement, 314,406 of the grant is to be repaid, by installments over the period from June 30, 2014 to June 30, 2023. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such re","filed_date":"2023-08-14","accession":"0001477932-23-006106","full_text":"https://origin.rootz.global/static/filing/0001477932-23-006106.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"VNRX","company":"VOLITIONRX LTD","exchange":"NYSE","sector":"In Vitro & In Vivo Diagnostic Substances","signal_type":"ai_adoption","strength":56,"match_count":7,"context":"omies continue to experience volatility in the wake of the COVID-19 pandemic. As a result of the pandemic, the Company previously experienced disruptions to its clinical trials, including patient enrollment and sample collection delays. Although the Company has taken steps to mitigate the impacts of the COVID-19 pandemic and the related developments, the extent to which the pandemic may impact its bu","filed_date":"2023-05-10","accession":"0001477932-23-003240","full_text":"https://origin.rootz.global/static/filing/0001477932-23-003240.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"170738b7a6fa150295fbbf3d2a88f6941503fc12e73e7b978ed0460b080d0d5b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"58643284b2d42e98c67087e263ea8cde92b228ee5655ee609e31452751bb14a9","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":10,"hourly_limit":500,"remaining":490,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}